Delaying second Pfizer dose leaves cancer patients at risk - researchers
A study from King’s College London and the Francis Crick Institute – which has not yet been peer reviewed – found that three weeks after the first jab antibody responses were found in 39% of people with solid cancers and 13% of people with blood cancer
Delaying the second dose of the Pfizer/BioNTech vaccine must be urgently reviewed for cancer patients after a single shot was found to offer inadequate protection, researchers have said.
A study from King's College London and the Francis Crick Institute – which has not yet been peer reviewed – found that three weeks after the first jab antibody responses were found in 39% of people with solid cancers and 13% of people with blood cancer, reports the Guardian.
This compared with 97% of people with no cancer, according to the research on 205 people – 151 with cancer and 54 healthy controls.
Keep updated, follow The Business Standard's Google news channel
Cancer patients given a second dose of the vaccine three weeks after the first – as recommended by Pfizer – had a much better immune response, with 95% of those with solid tumours showing detectable antibodies.
The team said leaving up to a 12-week gap between doses – the government's policy in the UK – was leaving cancer patients vulnerable to serious cases of Covid-19.
However, Cancer Research UK said the study was relatively small and people should continue to follow the advice of their doctors.
Dr Sheeba Irshad, a senior clinical lecturer at King's College London, said: "Our data provides the first real-world evidence of immune efficacy following one dose of the Pfizer vaccine in immunocompromised patient populations.
"We show that following first dose most solid and haematological [blood] cancer patients remained immunologically unprotected up until at least five weeks following primary injection, but this poor one-dose efficacy can be rescued with an early booster at day 21."
She added: "Based on our findings, we would recommend an urgent review of the vaccine strategy for clinically extremely vulnerable groups. Until then, it is important that cancer patients continue to observe all public health measures in place such as social distancing and shielding when attending hospitals, even after vaccination."
Prof Adrian Hayday, of King's College London and the Francis Crick Institute, said: "The vaccine is very impressive in its impact on healthy individuals and our study shows that it can clearly bring immense benefit to cancer patients too, but in most cases this is only after boosting.
"Cancer patients should be vaccinated and boosted quickly and their responses, particularly those of blood cancer patients, should be intensively monitored so that those who mix with family, friends and carers can be confident of their environment."
Martin Ledwick, the head information nurse at Cancer Research UK, said: "This is an interesting study and it's important to assess how cancer patients are responding to the vaccines being rolled out. But at this stage, we are looking at data that hasn't been peer reviewed, where other experts in the field would flag errors and limitations within the results.
"The numbers of patients looked at in the study are also relatively small, particularly for those with blood cancers. We know that this information could be worrying, but anyone undergoing cancer treatment should continue to follow the advice of their doctors, and we encourage all who can to take up the vaccine."
A Department of Health and Social Care spokesperson said: "We are focused on saving lives and the antibody response is only part of the protection provided by the vaccine. The independent Joint Committee on Vaccination and Immunisation, which advises government on vaccine use and prioritisation, regularly reviews data and evidence on vaccine efficacy and effectiveness."
